Genomic Health and Almac Group Enter Exclusive In-Licensing Agreement to Develop and Commercialize Anthracycline Chemotherapy Benefit Test for High Ri

27-11-2013 Business Wire HealthComments (0)

Genomic HealthPharmaceutical

Genomic Health, Inc. (Nasdaq: GHDX) and ALMAC GROUP Ltd jointly announced today that Genomic Health will exclusively license Almac Group’s technology and intellectual property to further develop, validate and subsequently commercialize a multi-gene test to predict benefit from DNA damage-based chemotherapy drugs, such as the commonly used anthracycline-based regimens, in breast cancer. Such a test would be particularly useful

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top